Skip to content
ZAP-X
ZAP-X Overview
ZAP-Axon Planning
Advancing Access
Installation Sites
Dynamic Spherical Delivery (DSD)
Clinical
Clinical Publications
Planning Studies
SRS Webinars
Company
About ZAP
Leadership
Career Opportunities
Patient Resources
News & Events
Newsroom
Meetings & Tradeshows
Media Resources
Contact
ZAP-X
ZAP-X Overview
ZAP-Axon Planning
Advancing Access
Installation Sites
Dynamic Spherical Delivery (DSD)
Clinical
Clinical Publications
Planning Studies
SRS Webinars
Company
About ZAP
Leadership
Career Opportunities
Patient Resources
News & Events
Newsroom
Meetings & Tradeshows
Media Resources
Contact
English
Español
Français
Italiano
简体字
日本語
English
Español
Français
Italiano
简体字
日本語
English
Español
Français
Italiano
简体字
日本語
English
Español
Français
Italiano
简体字
日本語
ZAP-X
About ZAP
Contact
ZAP-X
About ZAP
Contact
Newsroom
Press Releases
ZAP Surgical Receives Regulatory Approval in India
April 7, 2023
Read More
First ZAP-X Gyroscopic Radiosurgery Platform Installation in Poland
November 12, 2022
Read More
The Institut du Cancer Courlancy to Acquire ZAP-X Radiosurgery Platform
September 27, 2022
Read More
Neurosurgery One in Littleton, Colorado Treats First Patient with ZAP-X
August 29, 2022
Read More
Chairman of Foxconn Technology Joins Board of Directors
June 30, 2022
Read More
ZAP CEO, Dr. John R. Adler, Receives Prestigious Janeway Medal
May 26, 2022
Read More
Baptist Health South Florida to Acquire ZAP-X
April 27, 2022
Read More
Renown French Oncology Research Group Selects ZAP Surgical Technology
March 12, 2022
Read More
Commissioner of Patents Rejects Elekta’s Request to Reverse 2021 Decision Invalidating Its Patent Claims
March 9, 2022
Read More
Announcing Strategic Partnership and Multi-System Order with Apollo Hospitals
March 1, 2022
Read More
Announcing the Installation of Pioneering Radiosurgery Platform at Japanese Bullet Train Station
February 1, 2022
Read More
Inspiring the Expansion of Novel Non-Invasive Brain Tumor Procedures
January 11, 2022
Read More
Bringing Next-Gen Non-Invasive Brain Tumor Treatment to France
October 27, 2021
Read More
Bringing the Latest Non-Invasive Brain Tumor Treatment to Madrid
August 30, 2021
Read More
Installing a New Gyroscopic Radiosurgery Platform for Treating Brain Tumors
May 13, 2021
Read More
Upcoming: Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich
April 21, 2021
Read More
U.S. Patent and Trademark Office Rules Elekta Patent Claims Invalid
April 6, 2021
Read More
Announcing First ZAP-X Gyroscopic Radiosurgery Platform Installation in Florida
March 2, 2021
Read More
Closing 2020 with 18 New System Orders
February 11, 2021
Read More
ZAP-X Gyroscopic Radiosurgery Platform Receives CE Mark Clearance
February 2, 2021
Read More
ZAP-X Gyroscopic Radiosurgery Platform Receives Japanese Shonin Approval
October 7, 2020
Read More
Spine Neurosurgeons: Expand your Practice with SRS
September 29, 2020
Read More
First Facility on the East Coast to Initiate Patient Treatment
September 22, 2020
Read More
Bringing World-Class Brain Tumor Treatments to Rural Germany
February 19, 2020
Read More
Load More
ZAP Surgical Receives Regulatory Approval in India
April 7, 2023
Read More
First ZAP-X Gyroscopic Radiosurgery Platform Installation in Poland
November 12, 2022
Read More
The Institut du Cancer Courlancy to Acquire ZAP-X Radiosurgery Platform
September 27, 2022
Read More
Neurosurgery One in Littleton, Colorado Treats First Patient with ZAP-X
August 29, 2022
Read More
Chairman of Foxconn Technology Joins Board of Directors
June 30, 2022
Read More
ZAP CEO, Dr. John R. Adler, Receives Prestigious Janeway Medal
May 26, 2022
Read More
Baptist Health South Florida to Acquire ZAP-X
April 27, 2022
Read More
Renown French Oncology Research Group Selects ZAP Surgical Technology
March 12, 2022
Read More
Commissioner of Patents Rejects Elekta’s Request to Reverse 2021 Decision Invalidating Its Patent Claims
March 9, 2022
Read More
Announcing Strategic Partnership and Multi-System Order with Apollo Hospitals
March 1, 2022
Read More
Announcing the Installation of Pioneering Radiosurgery Platform at Japanese Bullet Train Station
February 1, 2022
Read More
Inspiring the Expansion of Novel Non-Invasive Brain Tumor Procedures
January 11, 2022
Read More
Bringing Next-Gen Non-Invasive Brain Tumor Treatment to France
October 27, 2021
Read More
Bringing the Latest Non-Invasive Brain Tumor Treatment to Madrid
August 30, 2021
Read More
Installing a New Gyroscopic Radiosurgery Platform for Treating Brain Tumors
May 13, 2021
Read More
Upcoming: Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich
April 21, 2021
Read More
U.S. Patent and Trademark Office Rules Elekta Patent Claims Invalid
April 6, 2021
Read More
Announcing First ZAP-X Gyroscopic Radiosurgery Platform Installation in Florida
March 2, 2021
Read More
Closing 2020 with 18 New System Orders
February 11, 2021
Read More
ZAP-X Gyroscopic Radiosurgery Platform Receives CE Mark Clearance
February 2, 2021
Read More
ZAP-X Gyroscopic Radiosurgery Platform Receives Japanese Shonin Approval
October 7, 2020
Read More
Spine Neurosurgeons: Expand your Practice with SRS
September 29, 2020
Read More
First Facility on the East Coast to Initiate Patient Treatment
September 22, 2020
Read More
Bringing World-Class Brain Tumor Treatments to Rural Germany
February 19, 2020
Read More
Load More
Media Resources
Download photography, logos and resources for the media.
Media Resources
Media Contact
For additional questions contact:
Mark Arnold
Senior VP, Marketing
Email Mark
About ZAP
Our vision for the future of brain cancer and the team fighting to make it happen.
Meet ZAP
Prior Revisions:
Treatment DELIVERY Manual
English:
E0920-00004
Group
Rev. E
Group
Rev. F
Group
Rev. H
Group
Rev. J
Group
Rev. K
Group
Rev. L
Group
Rev. M
Group
Rev. N
Deutsch:
E0920-00029
Group
Rev. A
Group
Rev. B
Group
Rev. C
Group
Rev. D
Español:
E0920-00034
Group
Rev. A
Group
Rev. B
Group
Rev. C
Français:
E0920-00035
Group
Rev. A
Group
Rev. B
Group
Rev. C
Group
Rev. D
Italiano:
E0920-00022
Group
Rev. A
Group
Rev. B
Group
Rev. C
Group
Rev. D
日本語:
E0920-00044
Group
Rev. A